PQRI PODP Extractables & Leachables Workshop

Similar documents
Introduction to E&Ls 1

CDER Risk Assessment to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products

Safety Thresholds and Best Practices for PODP Highlights of Day 1 & Day 2

Swiss Medic Training Sampling

ASEAN GUIDELINES FOR VALIDATION OF ANALYTICAL PROCEDURES

PART II VIII. CONCERNING CHEMICAL. PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION FOR RADIOPHARMACEUTICAL PRODUCTS.

Physicochemical Characterization of Acyclovir Topical Semisolid Dosage Forms Towards TCS Validation Flavian Ștefan Rădulescu, Dalia Simona Miron

Stability of pharmaceutical preparations

Determining Extractables and Leachables in Polymeric Materials

EXTRACTABLES & LEACHABLES Standard Protocols in Single Uses Technology

Parenteral and Ophthalmic Drug Products Leachables and Extractables Working Group

Compounding. Course Design hours lecture per week or 32 total hours Transfer Status

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) GUIDELINE ON RADIOPHARMACEUTICALS

OMICS International Conferences

Concept of Elemental Impurities (EI) assessment in finished dosage forms by total extraction testing

PQRI Stability Shelf-Life Working Group Glossary Ver 1 0.doc

PHRC 4110 Pharmaceutics I

why open access publication of stability date is essential Mark Santillo Regional QA Officer SW England

STUDY OF THE APPLICABILTY OF CONTENT UNIFORMITY AND DISSOLUTION VARIATION TEST ON ROPINIROLE HYDROCHLORIDE TABLETS

Data Sharing Initiatives Dr Andy Teasdale

applying a unique combination of disciplines consulting, preclinical, toxicology,

Peptides as Radiopharmaceuticals: CMC Perspectives

Analytical Methods Validation

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Characterization of Solid State Drugs by Calorimetry

PHARMACEUTICAL BULLETINS

The Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

The University of Jordan

Section II Assessing Polymers

Enquiry. Demonstration of Uniformity of Dosage Units using Large Sample Sizes. Proposal for a new general chapter in the European Pharmacopoeia

Preformulation & Solid State Chemistry Services

Christin T. Choma TA Instruments, 109 Lukens Drive, New Castle, DE 19720, USA

serve the goal of analytical lmethod Its data reveals the quality, reliability and consistency of

Independence and Dependence in Calibration: A Discussion FDA and EMA Guidelines

Standard Glossary of Packaging Inks and Coatings Terms

7/8/2013. What is GHS?

Apply knowledge of excipients, preformulation studies, stability formulation of pharmaceutical products and drug delivery systems.

High Pressure/Performance Liquid Chromatography (HPLC)

Analytical & Solid State Services. June 2017

ASAP: Accelerated Stability Assessment Program. Improved Protocol and Data Analysis for Accelerated Shelf-Life Estimation of Solid.

GHS Classification CONCEPT OF GHS

King Saud University College of Pharmacy Department of Pharmaceutics. Biopharmaceutics PHT 414. Laboratory Assignments 2010 G 1431 H

HAZARD COMMUNICATION PROGRAM 2015 UPDATE GHS AWARENESS TRAINING CSULB COE

Regulatory and Alternative Analytical Procedures are defined as follows 2 :

HACCP Concept. Overview of HACCP Principles. HACCP Principles. Preliminary Tasks Development of the HACCP Plan

Analytical Performance & Method. Validation

ORTHOGONAL PARTICLE CHARACTERIZATION TECHNIQUES FOR BIO-APPLICATIONS: AN INTRODUCTION TO DLS (DYNAMIC LIGHT SCATTERING), NTA (NANOPARTICLE

Overview of HACCP Principles. OFFICE OF THE TEXAS STATE CHEMIST Texas Feed and Fertilizer Control Service Agriculture Analytical Service

European Chemicals Agency (ECHA)Topical Scientific Workshop: Regulatory Challenges in Risk Assessment of Nanomaterials

Introduction to Pharmaceutical Chemical Analysis

Standard Practice for Heat Aging of Plastics Without Load 1

APPENDIX C. Modified ASTM C 1260 Test Method to Evaluate Aggregate Reactivity in Presence of Deicer Solutions

SAMM POLICY 5 (SP5) POLICY ON MEASUREMENT UNCERTAINTY REQUIREMENTS FOR SAMM TESTING LABORATORIES Issue 2, 28 February 2007 (Amd. 1, 11 August 2014)

HAZCOM - Training

Definition and regulation in terms of mechanism of action and intended use

Formulation of Low Dose Medicines - Theory and Practice

Using Design of Experiments to Optimize Chiral Separation

Reavis High School AP Chemistry Curriculum Snapshot

Hazard Communication for Dangerous and Harmful Materials

International Journal of Pharmacy and Pharmaceutical Sciences ISSN Vol 2, Suppl 3, 2010

CHEMISTRY 130 General Chemistry I. Five White Powders & Chemical Reactivity

The Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Purpose, scope and application

Risk Management under the. Chemicals Management Plan

University of Houston-Downtown

Guidance for Industry M4: The CTD General Questions and Answers

The University of Jordan. Pharmaceutical Technology II ( ) Office number . Office hours Day/Time Sunday Monday Tuesday Wednesday Thursday

Introduction to Bruker s Products and Solutions

Research and Development of Nanoparticle Characterization Methods

Chapter 4: Verification of compendial methods

Automated Stability Testing Delivering Rapid Product Development

Harmonisation of product notification. Ronald de Groot Dutch Poisons Information Center

Starting Materials For Active Substances

á233ñ ELEMENTAL IMPURITIES PROCEDURES

Chapter content. Reference

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

Chemical Inventory. Each area must maintain a complete, accurate and up to date chemical inventory. The inventory should include: All Chemicals

FACULTY OF PHARMACY. M. Pharmacy I Semester (Suppl.) Examination, November 2015 (Common To All) Subject: Pharmaceutical Analytical Techniques

Method Development and Validation Of Prasugrel Tablets By RP- HPLC

THE USE OF IONISING RADIATION IN THE MANUFACTURE OF MEDICINAL PRODUCTS

Cleaning Memo for January 2017 A Critique of the APIC Guideline

Substance identification and how to report it in IUCLID 6

Physical-Chemistry Factors Affecting Oral Absorption. Objectives. ph - Partition Theory. 27 September Chapter 23 1

Fundamentals Of Analytical Toxicology PDF

Guidance for Industry

Draft Guideline on Bioanalytical Method (Ligand Binding Assay) Validation in Pharmaceutical Development. (24 January, 2014, MHLW, Japan)

Prentice Hall. Chemistry, (Wilbraham) 2008, National SE, Georgia TE. Grades 9-12

Analytical Method Validation: An Updated Review

ICH Q3D: Practical implementation and the role of excipient data in a risk based approach. Dr Andrew Teasdale

MATERIAL AND EQUIPMENT STANDARD FOR. INHIBITOR FOR HYDROCHLORIC ACID AND HCl+HF DESCALING AND PICKLING SOLUTION FOR OIL AND GAS WELLS ORIGINAL EDITION

Chapter 1. Introduction

Safety Data Sheets (SDS)

DOWNLOAD OR READ : CHEMISTRY OF POWDER PRODUCTION PDF EBOOK EPUB MOBI

Setting Attainable and Practical Particle Size Specifications

SPRING GROVE AREA SCHOOL DISTRICT

Scientific Observations and Reaction Stoichiometry: The Qualitative Analysis and Chemical Reactivity of Five White Powders

Global Harmonization and Hazard Communication

Particle Size Analysis in the Pharmaceutical Industry

Opportunities for Regulatory Relief via In Vitro Dissolution. James E. Polli June 10, 2015

Introduction to Chromatography

Transcription:

PQRI PODP Extractables & Leachables Workshop The PODP Best Demonstrated Practice Chemistry Recommendations: Best Practices for Generating Extractable Profiles Presented by: Dennis Jenke, Chair, PQRI PODP Chemistry Working Team April 2018

PODP Best Demonstrated Practice Recommendations Chemistry: Background 2006: The Product Quality Research Institute (PQRI) issued a Recommendation entitled Safety Thresholds and Best Demonstrated Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products 1. The recommendation provided a scientific rationale and process to identify, quantify and establish the biological safety of leachables and/or extractables in OINDP. Included were Best Demonstrated Practices for performing Controlled Extraction Studies specifically for the OINDP dosage forms. 2008: The PQRI initiated an effort to extend the OINDP Recommendations to a second dosage form, Parenteral and Ophthalmic Drug Products (PODP). That organization s Chemistry Team hypothesizes that the good science best demonstrated practices that were established for the OINDP pharmaceutical development process can be extrapolated to container closure systems for PODP. 2 2013: The PQRI PODP Chemistry Team is ready to talk about some of its Best Demonstrated Practice Recommendations. 3 2016: The PQRI PODP Chemistry Team publishes the results of a simulation (migration) study. 4 2017 (2018): The PQRI PODP Best Demonstrated Practice Recommendations will be have been published. 2

What is a Best Demonstrated Practice Recommendation? A Best Demonstrated Practice Recommendation is a guide, made by recognized authorities in a relevant field of practice and proposed by an organization with a recognized and validated authority to do so, whose purpose is to direct and enable the practice of good science by competent practioneers in an effective, efficient, appropriate, rigorous and necessary manner. A Best Demonstrated Practice Recommendation is not: 1. A Standard 2. A Specification 3. A Compendial Monograph 4. A Regulatory Guidance or Guideline 5. A Rule or Law 6. A Commandment 7. A Cook Book 3

The Challenge facing the PODP Team 4

Attributes that OINDP and PODP Do Not Share: Daily Dose 5

Attributes that OINDP and PODP Do Not Share: Materials of Construction 6

7

Attributes that OINDP And PODP Do Not Share: Additional Attributes 1.Dosing Regimen: Acute versus Chronic. 2.Patient Population and Disease State Treated. 3.Heat History. 4.Others??? Bottom Line: It is not a trivial exercise to extrapolate the OINDP Conclusions and Recommendations to PODPs. 8

Overall Conclusion It is relevant and appropriate to note that 1. The data generated and experiences gained in the PODP studies, which were performed on materials relevant for PODP products and with methods appropriate for PODP dosage forms, and 2. The accumulated experiences and technical knowledge of the individual members of the PODP Chemistry Working Group support the spirit, if not the exact letter, of all the (OINDP) recommendations as they are applied to the PODP situation. 9

An OINDP Definition that is Adopted for PODP with Modification OINDP Definition: Controlled Extraction Study (CES) - a laboratory investigation into the qualitative and quantitative nature of extractables profiles of critical components of an OINDP container/closure system. PODP Definition: Controlled Extraction Study a laboratory investigation into the qualitative and quantitative nature of extractables profiles of a container/closure system and/or its critical components and materials of construction. Discussion: The language in the PODP Recommendation expands the scope of the CES to make it more generally applicable to all dosage forms and to include materials of construction to capture materials characterization studies. 10

OINDP Recommendations that Are Adopted with Minor Modification Controlled Extraction Studies (CES) should: Include careful sample preparation based on a knowledge of the analytical techniques used, Include a defined and systematic process for the identification of individual extractables, Include a re-examination of supplier information describing component formulation. 11

OINDP Recommendations Adopted for PODP with Modification OINDP Recommendation: Controlled Extraction Studies should be accomplished on all critical components incorporated into the container/closure systems of every type of OINDP. PODP Recommendation: Extractables and leachables assessments of drug products in semipermeable container closure systems (e.g., ODP in LDPE) must include packaging components that do not make direct drug product contact (e.g., labels, product information inserts, unit cartons ). Discussion: The semipermeable container closure systems that are more typically used with ophthalmic drug products are poor barriers and thus it is more likely that ophthalmic drug products would contain foreign impurities that are associated with secondary, tertiary and/or auxiliary sources. 12

OINDP Recommendations Adopted for PODP with Clarification OINDP Recommendation: A Controlled Extraction Study should include multiple analytical techniques. PODP Recommendation: A Controlled Extraction Study should utilize an analytical process with thoughtfully chosen multiple orthogonal analytical techniques for the purpose of discovering, identifying and quantifying relevant and appropriate extractables. Included in the analytical process is a consideration of the completeness of the analytical process. Discussion: The language in the PODP Recommendation captures concepts that were included in the OINDP Recommendations document but not specifically captured in the abbreviated OINDP Recommendation statement. 13

OINDP Recommendations Adopted for PODP with Clarification OINDP Recommendation: Scientifically justifiable analytical thresholds for extractables and leachables in OINDP can be established. PDP Recommendation: Scientifically justifiable analytical thresholds for extractables and leachables in PDP can be established. However: The absolute values of the analytical thresholds will differ, OINDP versus PODP, consistent with the inherent differences in these dosage forms, including their dosing and conditions of use. 14

OINDP Recommendations Adopted for PDP with Modification OINDP Recommendation: A Controlled Extraction Study should be guided by an Analytical Evaluation Threshold (AET) that is based on an accepted safety concern threshold. PDP Recommendation: A Controlled Extraction Study for a PDP should be guided by an Analytical Evaluation Threshold (AET) that is based on an accepted and relevant safety standard such as the safety concern threshold. Discussion: The OINDP Recommendation has been modestly expanded to include relevant and appropriate safety standards and thresholds other than the safety concern threshold, as the application of the SCT may not be appropriate for some dosage forms (e.g., ophthalmic). It is noted that use of the AET to guide the Controlled Extraction Study will affect the strategies and tactics used to design and complete the Study. 15

OINDP Recommendations Adopted for PDP with Modification A Controlled Extraction Study should: OINDP Recommendation: 1. Employ vigorous extraction with multiple solvents of varying polarity, and 2. Incorporate multiple extraction techniques. PODP Recommendation: Controlled extractions studies should use a combination of multiple extraction solvents and extraction techniques as appropriate for, and consistent with, the intent and purpose of the controlled extraction study. Discussion: The language in the PODP Recommendation captures concepts that were included in the OINDP Recommendations document but not specifically captured in the abbreviated OINDP Recommendation statement. 16

PODP Best Demonstrated Practice Recommendations Conditions for Performing Controlled Extraction Studies Although the PODP Chemistry Team published studies that involved performing controlled extraction and migration experiments 3,4, the conditions under which the studies were performed were not meant to be interpreted as recommendations for conditions that should be in any (or all) controlled extraction studies performed for the purpose of registering a packaging material or system or a packaged drug product. These studies were designed as an exercise in good and investigative science, not as examples of recommended practice. 17

Type of Controlled Extraction Studies Material characterization (i.e., identify and quantify the additives and ingredients in a material, as ingredients and additives may be used to forecast extractables), Packaging assessment (i.e., identify extractables as a means of forecasting leachables in a specific dosage form, simulation study), Quality Control (i.e., exercise control over the quality of incoming materials of construction for a packaging system). Change Control (i.e., respond to changes in the materials and/or processes associated with a packaging system. 18

The Simulation Study In situations of analytically challenging Analytical Evaluation Thresholds (AETs) for certain PDPs (e.g., large volume parenterals) and in other situations for ODPs, a specific type of extraction study termed a Simulation Study, could be applied (in lieu of) or to supplement and focus drug product leachables studies. These studies can establish an extractables profile representing the worst-case leachables profile of the packaged drug product that the study simulates. Table 3.3. Comparison of Key Operational Parameters, Simulation Study Versus Leachables Study Operational Parameter Value for Simulation Study Value for Leachables Study Test Sample Simulating solvent (s) Drug product Test System Marketed Packaging System 1 Marketed Packaging System Test Conditions Accelerated clinical use Clinical Use 2 Notes: 1 In some situations, a simulation study may use an exaggerated packaging system. For example, if the packaging system has a single port tube and the purpose of the study is to assess leachables derived from the port tube, then the exaggerated system could be constructed with two ports. 2 It is the case that leachables studies (for example leachables testing performed as part of a stability study) could also include accelerated clinical use conditions. 19

The Simulation Study An extractables profile obtained from a properly designed and executed simulation study will be equal to (or greater than) a leachables profile obtained for a drug product over its shelf-life. (meaning that the extractables profile includes all the members of the leachables profile with extractables levels being greater than or equal to the leachables levels). since the extractables profile is the same as the leachables profile, then one can safety assess the extractables profile and not perform subsequent leachables testing. The appropriateness of such an answer rests on the rigor of the simulation and its associated justification. 20

Designing a Simulation Study, Dimensions to Consider Solution Composition Dimensions of Contact Stoichiometry Temperature & Duration 21

Designing a Simulation Study, Solution Composition Solution Composition 1. Polarity 2. ph 3. Reactivity 22

Designing a Simulation Study, Solution Polarity Means of Establishing a Solution s Polarity: 1. Polarity Tables for Solvents 2. Correlation with Measurable Fundamental Properties Dielectric Constant 3. Use of Polarity Markers (e.g., solvatochromic Reichardt s dye) 4. Experimental determination via Extraction Power Scales 23

Designing a Simulation Study, Solution Polarity 5 90 80 y = 28.841x R² = 0.9904 % Ethanol 70 60 50 40 30 20% Lipid Emulsion 1% Polysorbate 80 25% Albumin 20 10 0 Water for Injection 0 0.5 1 1.5 2 2.5 3 (DEHP Conc, mg/l)^0.1 24

PODP Best Demonstrated Practice Recommendations Chemistry: Designing a Simulation Study, Solution ph The Effect of ph on the Solubility of an Acidic or Basic Extractable. The Figure considers an acidic or basic extractable with a pk a of 5.0 and a solubility of 100 (arbitrary units). As the ph of the extracting medium increases, the solubility of the acidic extractable increases. Similarly, as the ph of the extracting medium decreases, the solubility of a basic extractable increases. In general, the solubility of a neutral extractable is unaffected by ph. 6 25

PODP Best Demonstrated Practice Recommendations Chemistry: Designing a Simulation Study, Solution ph The solubility of non-ionics (DEP) is unaffected by ph. The solubility of the acids (AA, SA and MEHP) increases with increasing ph, depending on their pk a. The solubility of the bases (SAM, DBA, TDA, BTA) increases with decreasing ph, depending on their pk a. The Zone of Divergence spans ph values where the weakest acid (SA) and the weakest base (BTA) achieve their maximum solubilities. A set of extraction solvents that captures all possible acidic or basic extractables at their likely highest concentration must have a ph values that span the Zone of Divergence. 6 26

Designing a Simulation Study, Temperature and Duration Temperature and Duration 27

Designing a Simulation Study, Acceleration by Elevated Temperature 28

Designing a Simulation Study, Establishing Accelerated Conditions 1. ASTM F1980-07 (Reapproved 2016): Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices. Accelerated Aging Time at T2 = Actual Aging Time at T1 C C = Q 10 [(T2 T1)/10] where Q 10 = 10 C Reaction Rate Constant T2 = accelerating temperature ( C) T1 = actual temperature of contact ( C) 2. Factor 10 Rule 7, based on the observation that the diffusion coefficient increases by roughly an order of magnitude for every 20 C increase in contact temperature. Accelerated Aging Time at T2 = Actual Aging Time at T1 C C = 10 [(T2 T1)/20] 29

Designing a Simulation Study, Establishing Accelerated Conditions Relative Duration to Achieve a Given Concentration 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 20 30 40 50 60 70 80 Extraction Temperature, C 4 days using ASTM F1980-7 and a Q10 = 1.5 0.2 days using the factor 10 rule Q10 = 2.2 Q10 = 2.0 Q10 = 1.8 Q10 = 1.5 Factor 10 If it takes 20 days to achieve a concentration C at 25 C, it will take the following number of days to achieve the same concentration C at 65 C: 30

Designing a Simulation Study, Stoichiometry Stoichiometry 1. Surface area/solution volume 2. Material weight/solution volume 31

Designing a Simulation Study, SA/V Ratio As the surface area to solution volume ratio increases, the concentration of extractables will increase in a predictable manner 8 : C l,e = m l,e /V l = m p,o /[V l + (k p/l x SA p x t p )] Where C is the extractable s concentration, m is the mass of the extractable in either phase, SA is the surface area of the sample being extracted, t is the thickness of the sample being extracted, K p/l is the extractable s plastic/solution partition coefficient, V is the volume of either phase, and the subscripts p, l, e and o refer to the plastic phase, the liquid phase, equilibrium and original respectively 32

PODP Best Demonstrated Practice Recommendations Chemistry: Designing a Simulation Study, SA/V Ratio Theoretical Relationship between the Surface Area and the Extractable s Concentration at a Constant Extracting Solution Volume. The relationship is shown for extractables with polymer/liquid partition coefficients (k p/l ) ranging from 0.1 (extractable is highly soluble in the solution) to 1000 (extractable poorly soluble in the solution). 9 33

PODP Best Demonstrated Practice Recommendations Chemistry Cited References 1 Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products. PQRI Leachables and Extractables Working Group, September 9, 2006, available at http://www.pqri.org/pdfs/le- Recommendations-to-FDA-09-29-06.pdf. 2 PQRI. Parenteral and Ophthalmic Drug Products Work Plan; Product Quality Research Institute: Arlington, VA, 2008; available at http://www.pqri.org/commworking/minutes/pdfs/dptc/podpwg/addl/podp_work_plan_schedule.pdf. 3 D. Jenke, J. Castner, T. Egert, T Feinberg, A. Hendricker, C. Houston, D.G. Hunt, M. Lynch, A. Shaw, K. Nicholas, D.L. Norwood, D. Paskiet, M. Ruberto, E.J. Smith, F. Holcomb. Extractables characterization of five materials of construction representative of packaging systems used for parenteral and ophthalmic drug products. PDA J Pharm Sci Technol. 76(5): 448-511 (2013). 4 D. Jenke, T. Egert, A. Hendricker, J. Castner, T. Feinberg, C. Houston, D.G. Hunt, M. Lynch, L. Markovic, K. Nicholas, D.L. Norwood, D. Paskiet, M. Ruberto, E.J. Smith, and F. Holcomb. Simulated Leaching (Migration) Study for a Model Container-closure System Applicable to Parenteral and Ophthalmic Drug Products (PODPs). PDA J Pharm Sci Technol. 71(2): 68-87 (2017). 5 D. Jenke, N. Liu, Y. Hua, S. Swanson, and R. Bogseth. A means for establishing and justifying binary ethanol/water mixtures as simulating solvents in extractables studies. PDA J Pharm Sci Technol. 69(3): 366-382 (2015). 6 D. Jenke. Establishing the proper ph of simulating solvents used in organic extractables assessments for packaging systems and their materials of construction used with aqueous parenteral drug products. Pharm Outsourcing. 15(4):20, 22, 24-27 (2014) 7 R. Franz, A. Stormer. Migration of Plastic Constituents. In Plastic Packaging: Interactions with Foods and Pharmaceuticals. Wiley-VCH; Second Edition, 2008, pp. 368. 8 R. Franz, A. Stormer. Ibid, pp. 370. 9 D. Jenke and B. Rabinow. Proper accounting for surface area to solution volume ratios in exaggerated extractions. PDA J Pharm Sci Technol. 71(3): 225-233 (2017) 34

PDP Best Demonstrated Practice Recommendations Chemistry A New Issue - Compatibility Issues with Biopharmaceuticals Quality assessments for biotherapeutics would include identifying and mitigating risks related to the following: Changes in the dosage form purity, safety, stability Changes in the product appearance, physicochemical and molecular structure Loss of potency due to absorption or adsorption of the active drug substance Degradation of the active drug substance induced by a leachable Reduction in the concentration of API or excipient due to absorption or adsorption Leachable-induced changes in formulation ph, product degradation, precipitation, aggregation Changes in the packaging component or system (discoloration, surface, function, brittleness etc.) 35

PDP and ODP Best Demonstrated Practice Recommendations Chemistry. Questions? Contact the presenter at: dennisjenke@triadscientificsolutions.com www.triadscientificsolutions.com 36